Seres Therapeutics (MCRB) Consolidated Net Income (2016 - 2024)
Historic Consolidated Net Income for Seres Therapeutics (MCRB) over the last 10 years, with Q3 2024 value amounting to $139.8 million.
- Seres Therapeutics' Consolidated Net Income rose 214431.93% to $139.8 million in Q3 2024 from the same period last year, while for Jun 2025 it was $139.8 million, marking a year-over-year increase of 61261.64%. This contributed to the annual value of $125.9 million for FY2024, which is 6478.68% up from last year.
- Seres Therapeutics' Consolidated Net Income amounted to $139.8 million in Q3 2024, which was up 214431.93% from -$6.7 million recorded in Q2 2024.
- In the past 5 years, Seres Therapeutics' Consolidated Net Income registered a high of $139.8 million during Q3 2024, and its lowest value of -$71.5 million during Q1 2023.
- Moreover, its 5-year median value for Consolidated Net Income was -$20.2 million (2020), whereas its average is -$13.1 million.
- Per our database at Business Quant, Seres Therapeutics' Consolidated Net Income tumbled by 19726.9% in 2023 and then surged by 214431.93% in 2024.
- Over the past 5 years, Seres Therapeutics' Consolidated Net Income (Quarter) stood at -$18.0 million in 2020, then crashed by 175.35% to -$49.7 million in 2021, then skyrocketed by 95.58% to -$2.2 million in 2022, then tumbled by 197.27% to -$6.5 million in 2023, then soared by 2240.73% to $139.8 million in 2024.
- Its Consolidated Net Income was $139.8 million in Q3 2024, compared to -$6.7 million in Q2 2024 and -$7.2 million in Q1 2024.